A股異動 | 江山股份(600389.SH)跌停 擬終止重大資產重組事項
格隆匯12月2日丨江山股份(600389.SH)一字板跌停,封單金額高達5.5億元。現報40.93元,總市值121.5億元。公司昨日晚間擬終止重大資產重組事項,隨即上交所要求説明重組終止是否損害上市公司利益等。據悉,在草甘膦價格持續上漲下,重組也引發資金的追捧。自4月份以來,江山股份漲幅十分明顯,截至昨日收盤,期間漲幅達114.84%。然而,令人意外的是,這場重組卻在昨日晚突然宣佈終止。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.